Latest News - AbbVie
Top Corporates Hub
AbbVie
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
16.09.2026 13:00
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
15.09.2026 13:00
AbbVie (NYSE: ABBV), together with BioLabs University of Toronto, today announced the opening of applications for the AbbVie Biotech Innovators Award during the Life Sciences Ontario Ideas to Action Forum in Toronto. The award aims to support the growth of Ontario's life sciences sector by helping promising early-stage biotechnology companies accelerate the development of innovative healthcare solutions.
AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
15.09.2026 12:30
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR today announced a partnership naming AbbVie the Official Pharmaceutical Sponsor of the PGA TOUR and the 2026 Presidents Cup. Through this new partnership, AbbVie introduces Birdies for Brain Health, a multi-year, purpose-driven campaign that turns birdies into more than a score by raising awareness and advancing support for people living with brain health conditions and their care partners.
Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
15.09.2026 12:00
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will bring its scientific leadership to the 2026 Science of Skin Summit (SSS), taking place Sept. 17-20 in Austin, Texas, through expert programming and on-site education focused on skin longevity, aging biology, regenerative aesthetics and emerging exosome research. Company R&D leaders will examine the hallmarks of aging, discuss how rigorous evidence can inform skincare innovation and introduce the FACTS Principles developed by SkinMedica®,
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
10.09.2026 17:46
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
10.09.2026 12:55
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults.1 These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks.
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
10.09.2026 12:41
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
HSBC Maintains Buy on AbbVie, Raises Price Target to $315
10.09.2026 10:10
HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.
Pfizer: Firing On All Cylinders
10.09.2026 09:21
Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough. Read why PFE stock is a buy.
AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting...
10.09.2026 08:58
These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent
VERAXA Biotech Designates Raju Willener as CFO
09.09.2026 15:46
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.
Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca
08.09.2026 08:08
Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
04.09.2026 14:59
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
04.09.2026 14:48
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
04.09.2026 13:00
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
04.09.2026 11:56
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
04.09.2026 09:19
AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
04.09.2026 03:07
AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
04.09.2026 01:24
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
American Century Focused Global Growth Fund Q2 2026 Portfolio Review
13.08.2026 04:40
Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.